Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jun;41(6):1275–1280. doi: 10.1128/aac.41.6.1275

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients.

V Heinemann 1, D Bosse 1, U Jehn 1, B Kähny 1, K Wachholz 1, A Debus 1, P Scholz 1, H J Kolb 1, W Wilmanns 1
PMCID: PMC163899  PMID: 9174183

Abstract

The liposomal formulation of amphotericin B (AmBisome) greatly reduces the acute and chronic side effects of the parent drug. The present study describes the pharmacokinetic characteristics of AmBisome applied to 10 patients at a dose of 2.8 to 3.0 mg/kg of body weight and compares them to the pharmacokinetics observed in 6 patients treated with amphotericin B deoxycholate at the standard dose of 1.0 mg/kg. Interpatient variabilities of amphotericin B peak concentrations (Cmax) and areas under concentration-time curves (AUC) were 8- to 10-fold greater for patients treated with AmBisome than for patients treated with amphotericin B deoxycholate. At the threefold greater dose of AmBisome, median Cmaxs were 8.4-fold higher (14.4 versus 1.7 microg/ml) and median AUCs exceeded those observed with amphotericin B deoxycholate by 9-fold. This was in part explained by a 5.7-fold lower volume of distribution (0.42 liters/kg) in AmBisome-treated patients. The elimination of amphotericin B from serum was biphasic for both formulations. However, the apparent half-life of elimination was twofold shorter for AmBisome (P = 0.03). Neither hemodialysis nor hemofiltration had a significant impact on AmBisome pharmacokinetics as analyzed in one patient. In conclusion, the liposomal formulation of amphotericin B significantly (P = 0.001) reduces the volume of drug distribution, thereby allowing for greater drug concentrations in serum. The low toxicity of AmBisome therefore cannot readily be explained by its serum pharmacokinetics.

Full Text

The Full Text of this article is available as a PDF (170.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler-Moore J. P., Chiang S. M., Satorius A., Guerra D., McAndrews B., McManus E. J., Proffitt R. T. Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome). J Antimicrob Chemother. 1991 Oct;28 (Suppl B):63–71. doi: 10.1093/jac/28.suppl_b.63. [DOI] [PubMed] [Google Scholar]
  2. Anaissie E., Paetznick V., Proffitt R., Adler-Moore J., Bodey G. P. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis. 1991 Aug;10(8):665–668. doi: 10.1007/BF01975823. [DOI] [PubMed] [Google Scholar]
  3. Bindschadler D. D., Bennett J. E. A pharmacologic guide to the clinical use of amphotericin B. J Infect Dis. 1969 Oct;120(4):427–436. doi: 10.1093/infdis/120.4.427. [DOI] [PubMed] [Google Scholar]
  4. Burch P. A., Karp J. E., Merz W. G., Kuhlman J. E., Fishman E. K. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol. 1987 Dec;5(12):1985–1993. doi: 10.1200/JCO.1987.5.12.1985. [DOI] [PubMed] [Google Scholar]
  5. Chopra R., Blair S., Strang J., Cervi P., Patterson K. G., Goldstone A. H. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):93–104. doi: 10.1093/jac/28.suppl_b.93. [DOI] [PubMed] [Google Scholar]
  6. Christiansen K. J., Bernard E. M., Gold J. W., Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985 Nov;152(5):1037–1043. doi: 10.1093/infdis/152.5.1037. [DOI] [PubMed] [Google Scholar]
  7. Collette N., van der Auwera P., Lopez A. P., Heymans C., Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989 Mar;33(3):362–368. doi: 10.1128/aac.33.3.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Feldman H. A., Hamilton J. D., Gutman R. A. Amphotericin B therapy in an anephric patient. Antimicrob Agents Chemother. 1973 Sep;4(3):302–305. doi: 10.1128/aac.4.3.302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fields B. T., Jr, Bates J. H., Abernathy R. S. Amphotericin B serum concentrations during therapy. Appl Microbiol. 1970 Jun;19(6):955–959. doi: 10.1128/am.19.6.955-959.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gallis H. A., Drew R. H., Pickard W. W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990 Mar-Apr;12(2):308–329. doi: 10.1093/clinids/12.2.308. [DOI] [PubMed] [Google Scholar]
  11. Gondal J. A., Swartz R. P., Rahman A. Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice. Antimicrob Agents Chemother. 1989 Sep;33(9):1544–1548. doi: 10.1128/aac.33.9.1544. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gray A., Morgan J. Liposomes in haematology. Blood Rev. 1991 Dec;5(4):258–272. doi: 10.1016/0268-960x(91)90017-7. [DOI] [PubMed] [Google Scholar]
  13. Gregoriadis G., Florence A. T. Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs. 1993 Jan;45(1):15–28. doi: 10.2165/00003495-199345010-00003. [DOI] [PubMed] [Google Scholar]
  14. Gregoriadis G. Overview of liposomes. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):39–48. doi: 10.1093/jac/28.suppl_b.39. [DOI] [PubMed] [Google Scholar]
  15. Humphreys H., Oliver D. A., Winter R., Warnock D. W. Liposomal amphotericin B and continuous venous-venous haemofiltration. J Antimicrob Chemother. 1994 May;33(5):1070–1071. doi: 10.1093/jac/33.5.1070-a. [DOI] [PubMed] [Google Scholar]
  16. Janknegt R., de Marie S., Bakker-Woudenberg I. A., Crommelin D. J. Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clin Pharmacokinet. 1992 Oct;23(4):279–291. doi: 10.2165/00003088-199223040-00004. [DOI] [PubMed] [Google Scholar]
  17. Joly V., Saint-Julien L., Carbon C., Yeni P. Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture. J Pharmacol Exp Ther. 1990 Oct;255(1):17–22. [PubMed] [Google Scholar]
  18. Khoo S. H., Bond J., Denning D. W. Administering amphotericin B--a practical approach. J Antimicrob Chemother. 1994 Feb;33(2):203–213. doi: 10.1093/jac/33.2.203. [DOI] [PubMed] [Google Scholar]
  19. Lopez-Berestein G., Bodey G. P., Fainstein V., Keating M., Frankel L. S., Zeluff B., Gentry L., Mehta K. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med. 1989 Nov;149(11):2533–2536. [PubMed] [Google Scholar]
  20. Lopez-Berestein G. Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother. 1987 May;31(5):675–678. doi: 10.1128/aac.31.5.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Lopez-Berestein G., Mehta R., Hopfer R. L., Mills K., Kasi L., Mehta K., Fainstein V., Luna M., Hersh E. M., Juliano R. Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis. 1983 May;147(5):939–945. doi: 10.1093/infdis/147.5.939. [DOI] [PubMed] [Google Scholar]
  22. Mehta R., Lopez-Berestein G., Hopfer R., Mills K., Juliano R. L. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta. 1984 Mar 14;770(2):230–234. doi: 10.1016/0005-2736(84)90135-4. [DOI] [PubMed] [Google Scholar]
  23. Meunier F., Prentice H. G., Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):83–91. doi: 10.1093/jac/28.suppl_b.83. [DOI] [PubMed] [Google Scholar]
  24. Proffitt R. T., Satorius A., Chiang S. M., Sullivan L., Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):49–61. doi: 10.1093/jac/28.suppl_b.49. [DOI] [PubMed] [Google Scholar]
  25. Sculier J. P., Coune A., Meunier F., Brassinne C., Laduron C., Hollaert C., Collette N., Heymans C., Klastersky J. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol. 1988 Mar;24(3):527–538. doi: 10.1016/s0277-5379(98)90033-5. [DOI] [PubMed] [Google Scholar]
  26. Szoka F. C., Jr, Milholland D., Barza M. Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother. 1987 Mar;31(3):421–429. doi: 10.1128/aac.31.3.421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wasan K. M., Grossie V. B., Jr, Lopez-Berestein G. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous intralipid infusion. Antimicrob Agents Chemother. 1994 Sep;38(9):2224–2226. doi: 10.1128/aac.38.9.2224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. van Etten E. W., Otte-Lambillion M., van Vianen W., ten Kate M. T., Bakker-Woudenberg A. J. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother. 1995 Apr;35(4):509–519. doi: 10.1093/jac/35.4.509. [DOI] [PubMed] [Google Scholar]
  29. van Etten E. W., van den Heuvel-de Groot C., Bakker-Woudenberg I. A. Efficacies of amphotericin B-desoxycholate (Fungizone), liposomal amphotericin B (AmBisome) and fluconazole in the treatment of systemic candidosis in immunocompetent and leucopenic mice. J Antimicrob Chemother. 1993 Nov;32(5):723–739. doi: 10.1093/jac/32.5.723. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES